Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Non-Current Deferred Tax Liability (2018 - 2024)

BioNexus Gene Lab's Non-Current Deferred Tax Liability history spans 7 years, with the latest figure at $13646.0 for Q3 2024.

  • For Q3 2024, Non-Current Deferred Tax Liability fell 52.75% year-over-year to $13646.0; the TTM value through Sep 2024 reached $13646.0, down 52.75%, while the annual FY2023 figure was $12255.0, 60.3% down from the prior year.
  • Non-Current Deferred Tax Liability for Q3 2024 was $13646.0 at BioNexus Gene Lab, up from $11918.0 in the prior quarter.
  • Across five years, Non-Current Deferred Tax Liability topped out at $30866.0 in Q4 2022 and bottomed at $1796.0 in Q3 2021.
  • The 5-year median for Non-Current Deferred Tax Liability is $19593.5 (2022), against an average of $17840.3.
  • The largest annual shift saw Non-Current Deferred Tax Liability surged 1452.12% in 2022 before it plummeted 61.16% in 2024.
  • A 5-year view of Non-Current Deferred Tax Liability shows it stood at $1872.0 in 2020, then surged by 1417.95% to $28416.0 in 2021, then increased by 8.62% to $30866.0 in 2022, then crashed by 60.3% to $12255.0 in 2023, then rose by 11.35% to $13646.0 in 2024.
  • Per Business Quant, the three most recent readings for BGLC's Non-Current Deferred Tax Liability are $13646.0 (Q3 2024), $11918.0 (Q2 2024), and $11916.0 (Q1 2024).